James Crowe

Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.
July 3, 2020

Research team isolates antibodies that may prevent rare polio-like illness in children linked to a respiratory infection

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.

By VUMC News and Communications
May 14, 2020

Antibodies eye Pacific Island “fever”

Vanderbilt Vaccine Center team isolates monoclonal antibodies against Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months.

By Bill Snyder
April 30, 2020

Antibody finding raises hopes for Marburg, COVID-19 treatments

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody “cocktails” to counter viral infection.

By Bill Snyder
April 17, 2020

School of Medicine quickly designs new teaching strategies

COVID-19 — and the mandate for social distancing to curb its spread — has meant rethinking how nearly 400 Vanderbilt University School of Medicine students will master the clinical and didactic skills they need to stay on course.

By Kathy Whitney
April 8, 2020

Vanderbilt University Medical Center and AstraZeneca join forces to identify potential COVID-19 treatments

Vanderbilt University Medical Center and the global biopharmaceutical company AstraZeneca have joined forces to identify candidates for antibody-based treatments that could protect people exposed to the 2019 novel coronavirus disease, COVID-19.

By Bill Snyder
March 30, 2020

StrategyShare2020 postponed; tune in to Virtual Discover, Learn & Share lectures

In light of the need to prioritize our unified response to COVID-19, StrategyShare2020, originally scheduled for June 24, is being postponed until further notice.

By Jill Clendening
March 23, 2020

Researchers developing potential coronavirus antibody therapies

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19.
By Bill Snyder
February 6, 2020

Antibody mixture may help block Ebola virus infection

A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus.
By Bill Snyder
February 6, 2020

Carnahan named associate director of Vaccine Center

Robert Carnahan, PhD, associate professor of Pediatrics and Radiology and Radiological Sciences, has been appointed associate director of the Vanderbilt Vaccine Center.
By Bill Snyder
January 23, 2020

Antibody isolated at VUMC found to halt dengue virus

Using part of an antibody isolated at Vanderbilt that “broadly neutralizes” the human dengue virus, biologists at the University of California San Diego and colleagues have disarmed the mosquito that transmits the disabling and potentially deadly tropical infection.
By Bill Snyder
December 12, 2019

VUMC-led team isolates antibody that blocks bird flu

VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans.
By Bill Snyder
September 13, 2019

Early effort to thwart chikungunya infection shows positive results

Phase 1 trial results in new approach to combat the chikungunya
By Bill Snyder
September 4, 2019

Partnership to help bring Zika virus therapy to clinic

Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago.
By Bill Snyder
1 … 3 4 5 6 7 … 13